12,372 trials
Schizophrenia
Primary: Percentage of Patients Meeting Exacerbation of Psychotic Symptoms/Impending Relapse Criteria by the End of Week 26 — 7.12; 7.76; 21.80 Percentage of patients — p=0.7871
Gastroesophageal Reflux
Primary: Determination of Median Time to Sustained Partial Response as Defined by Reduction in Likert Severity Scale Used to Assess Pain Associated With Heartburn in the Patient…
Multiple Sclerosis
Primary: Change From Baseline in Walking Speed Near Maximum Plasma Concentration at Steady State (CmaxSS) of Placebo and Dalfampridine-ER (5mg and 10mg), Using the Timed 25 Foot…
Blood Coagulation Disorders · Acute Major Bleeding
Primary: Percentage of Participants Achieving Hemostatic Efficacy of Stopping an Ongoing Major Bleed — 72.4; 65.4 percentage of participants
Pulmonary Disease, Chronic Obstructive
Primary: Number of Participants With Any Non-serious Adverse Event (AE) and Any Serious Adverse Event (SAE) Throughout the Treatment Period — 36; 93; 10; 23 Participants
Urea Cycle Disorders
Primary: The Primary Endpoint Was the 24-hour Area Under the Curve for Blood Ammonia (NH324-hour AUC) on Days 14 and 28. — 976.6; 865.35 μmol∙h/L
Rhinitis
Primary: Number of Participants With Any Non-serious Adverse Event (AE) and Any Serious Adverse Event (SAE) — 41; 0 participants
Pulmonary Hypertension
Primary: Peak 6-minute Walk Distance — 366.0; 360.0; 21.6; 3.0 meters — p=0.00044
Symptomatic Cervical Disc Disease
Primary: Overall Clinical Success (NDI, Fusion, Additional Surgical Procedures) — 5; 33; 28; 2 participants
Psoriasis
Primary: PASI 75 Response at Week 24 — 77.3; 60.3 Percentage of participants — p=<0.0001
Pulmonary Disease, Chronic Obstructive
Primary: Mean Change From Baseline (BL) in Aortic Pulse Wave Velocity (aPWV) at the End of the 12-week Treatment Period (Day 84) — -0.859; -1.118 meters per second (m/sec)…
Asthma
Primary: Number of Participants With Any Non-serious Adverse Event (AE) and Any Serious Adverse Event (SAE) — 4; 7; 1; 52 Participants
Alcoholism · Sleep Initiation and Maintenance Disorders
Primary: Sleep Efficiency (From an In-laboratory Polysomnogram) — 70.70; 78.63; 79.45; 82.80 percentage — p=0.49
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Forced Expiratory Volume in 1 Second Area Under the Curve (FEV1 AUC) 0-12 — 1.69; 1.56 liters
Colon Cancer
Primary: Efficacy - Preparation Quality Using a 4 Point Scale — 90; 84 percentage of participants